A groundbreaking 10-year clinical trial has confirmed that a shorter, two-week course of radiotherapy is just as effective as the traditional eight-week regimen for men with prostate cancer. This discovery could significantly reduce treatment time, hospital visits, and healthcare costs—while maintaining survival outcomes.
Study Overview and Key Results
The study, known as the CHHiP trial (Conventional or Hypofractionated High-dose Intensity Modulated Radiotherapy for Prostate Cancer), followed over 3,200 men with localized prostate cancer. Patients received either standard radiotherapy over eight weeks or a hypofractionated schedule completed in just two weeks.
After a decade of follow-up, researchers found that:
- Failure-free survival was 72% in the two-week group vs. 65% in the standard group.
- Prostate cancer-specific mortality was 4% in both groups.
- Overall survival remained comparable: 81% in the two-week group vs. 79% in the standard group.
Patient Quality of Life Maintained
Importantly, the shorter treatment did not increase long-term urinary or bowel side effects. According to Bioengineer.org, most side effects were mild to moderate, and patients reported a similar quality of life between both groups.
Dr. Emma Hall from the Institute of Cancer Research noted,
“Our findings support using shorter radiotherapy courses for prostate cancer, which can reduce treatment burden without sacrificing effectiveness.”
Implications for Cancer Care
This study adds to growing evidence supporting hypofractionated radiotherapy. According to a Harvard Health report, short-course treatments are gaining traction as they minimize disruption to patients’ lives while maintaining clinical results.
Increased adoption could help healthcare systems manage caseloads more efficiently. A JAMA Oncology analysis also showed a rise in hypofractionated radiotherapy use between 2004 and 2020.
Expert Support
Radiation oncologists and urologists have praised the findings. According to Urology Times, clinicians are increasingly recommending short-course therapy for suitable patients, especially during times when reducing hospital exposure is beneficial.
Therefore, patients with localized prostate cancer now have a proven, shorter treatment alternative that is both effective and convenient.
Explore More :
https://innovatemed.org
Disclaimer: This article is for informational purposes only and does not substitute professional medical advice. Always consult a qualified healthcare provider.
